Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2018 1
2019 1
2020 5
2021 2
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Clinical Relevance of BRCA1 Promoter Methylation Testing in Patients with Ovarian Cancer.
Blanc-Durand F, Tang R, Pommier M, Nashvi M, Cotteret S, Genestie C, Le Formal A, Pautier P, Michels J, Kfoury M, Hervé R, Mengue S, Wafo E, Elies A, Miailhe G, Uzan J, Rouleau E, Leary A. Blanc-Durand F, et al. Among authors: le formal a. Clin Cancer Res. 2023 Aug 15;29(16):3124-3129. doi: 10.1158/1078-0432.CCR-22-3328. Clin Cancer Res. 2023. PMID: 37067532
Homologous recombination deficiency (HRD) testing on cell-free tumor DNA from peritoneal fluid.
Roussel-Simonin C, Blanc-Durand F, Tang R, Vasseur D, Le Formal A, Chardin L, Yaniz E, Gouy S, Maulard A, Scherier S, Sanson C, Lacroix L, Cotteret S, Mauny L, Zaccarini F, Rouleau E, Leary A. Roussel-Simonin C, et al. Among authors: le formal a. Mol Cancer. 2023 Nov 6;22(1):178. doi: 10.1186/s12943-023-01864-1. Mol Cancer. 2023. PMID: 37932736 Free PMC article.
Clinical utility of SMARCA4 testing by immunohistochemistry in rare ovarian tumours.
Genestie C, Blanc-Durand F, Auguste A, Pautier P, Dunant A, Scoazec JY, Gouy S, Morice P, Bentivegna E, Maulard A, LeFormal A, Devouassoux-Shisheboran M, Leary A. Genestie C, et al. Br J Cancer. 2020 Feb;122(4):564-568. doi: 10.1038/s41416-019-0687-z. Epub 2019 Dec 17. Br J Cancer. 2020. PMID: 31844183 Free PMC article.
Changes in DNA Damage Response Markers with Treatment in Advanced Ovarian Cancer.
Kubelac P, Genestie C, Auguste A, Mesnage S, Le Formal A, Pautier P, Gouy S, Morice P, Bentivegna E, Maulard A, Adam J, Achimas-Cadariu P, Leary A. Kubelac P, et al. Among authors: le formal a. Cancers (Basel). 2020 Mar 17;12(3):707. doi: 10.3390/cancers12030707. Cancers (Basel). 2020. PMID: 32192091 Free PMC article.
Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer.
Leary A, Genestie C, Blanc-Durand F, Gouy S, Dunant A, Maulard A, Drusch F, Cheaib B, Michels J, Bentivegna E, LeFormal A, Mesnage S, Morice P, Pautier P, Khairallah AS. Leary A, et al. Cancer Immunol Immunother. 2021 Feb;70(2):519-531. doi: 10.1007/s00262-020-02670-0. Epub 2020 Aug 27. Cancer Immunol Immunother. 2021. PMID: 32852603 Free PMC article.
Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) beyond SMARCA4 Mutations: A Comprehensive Genomic Analysis.
Auguste A, Blanc-Durand F, Deloger M, Le Formal A, Bareja R, Wilkes DC, Richon C, Brunn B, Caron O, Devouassoux-Shisheboran M, Gouy S, Morice P, Bentivegna E, Sboner A, Elemento O, Rubin MA, Pautier P, Genestie C, Cyrta J, Leary A. Auguste A, et al. Among authors: le formal a. Cells. 2020 Jun 19;9(6):1496. doi: 10.3390/cells9061496. Cells. 2020. PMID: 32575483 Free PMC article.
Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative.
Auguste A, Genestie C, De Bruyn M, Adam J, Le Formal A, Drusch F, Pautier P, Crosbie EJ, MacKay H, Kitchener HC, Powell M, Pollock PM, Mileshkin L, Edmondson RJ, Nout R, Nijman HW, Creutzberg CL, Bosse T, Leary A. Auguste A, et al. Among authors: le formal a. Mod Pathol. 2018 Dec;31(12):1851-1861. doi: 10.1038/s41379-018-0055-1. Epub 2018 Jun 28. Mod Pathol. 2018. PMID: 29955143 Free article.
MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array.
Albiges L, Guegan J, Le Formal A, Verkarre V, Rioux-Leclercq N, Sibony M, Bernhard JC, Camparo P, Merabet Z, Molinie V, Allory Y, Orear C, Couvé S, Gad S, Patard JJ, Escudier B. Albiges L, et al. Among authors: le formal a. Clin Cancer Res. 2014 Jul 1;20(13):3411-21. doi: 10.1158/1078-0432.CCR-13-2173. Epub 2014 Mar 21. Clin Cancer Res. 2014. PMID: 24658158
11 results